CV Sciences Q2 FY26 net loss widens to USD 775,000; revenue drops 17.5% to USD 3 million vs Q2 FY25

• CV Sciences posted a GAAP net loss of USD 775,000 for Q2 2026, widening from a GAAP net loss of USD 261,000.
• Revenue fell 17.5% year over year to USD 3 million, down from USD 3.6 million.
• Gross margin slipped 2.3 percentage points to 48.6%.
• Operating loss widened to USD 301,000 from USD 131,000, while operating expenses declined 11.3% to USD 1.7 million.
• Adjusted EBITDA turned to a loss of USD 100,000 from positive adjusted EBITDA of USD 100,000; cash ended the quarter at USD 300,000.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CV Sciences Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202608131600ACCESSWRNAPR_____1207078) on August 13, 2026, and is solely responsible for the information contained therein.